Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vistagen Therapeutics Inc (NQ: VTGN )

2.860 +0.020 (+0.70%)
Streaming Delayed Price Updated: 11:48 AM EST, Dec 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Vistagen Therapeutics Inc

< Previous 1 2 3 4 5 6 7 Next >
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Schedules Release of Q1 2024 Numbers, Corporate Update Conference Call
Via Investor Brand Network
Vistagen To Report First Quarter Financial Results and Host Corporate Update Conference Call on August 10, 2023
From Vistagen
Via Business Wire
VistaGen Therapeutics Inc. (NASDAQ: VTGN) Near the Top of Equities by Percentage Gain on 8/7
Via Investor Brand Network
InvestorNewsBreaks – VistaGen Therapeutics Inc.’s (NASDAQ: VTGN) Fasedienol Demonstrates Potential to Transform Treatment Landscape for Social Anxiety Disorder
Via Investor Brand Network
Vistagen Announces Positive Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder
From Vistagen
Via Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces New Preclinical Data Further Demonstrating Unique Mechanism of Action for Itruvone (‘PH10’)
Via Investor Brand Network
Vistagen Reports New Preclinical Data Supporting Itruvone (PH10) Nasal Spray’s Potential Antidepressant Activity via Peripheral Nasal Neurons without Entry into the Brain
From Vistagen
Via Business Wire
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Announces Receipt from CIPO of Notice of Allowance for Dyskinesia Treatment
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Vistagen Receives Notice of Allowance for AV-101 Canadian Patent for Treatment of Dyskinesia Related to Levodopa Therapy for Parkinson’s Disease
From Vistagen
Via Business Wire
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Releases FY 2023 Financial Report, Corporate Update
Via Investor Brand Network
Vistagen Provides Corporate Update and Reports Fiscal Year 2023 Financial Results
From Vistagen
Via Business Wire
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Scheduled Conference Call to Report on FY 2023 Financial Numbers
Via Investor Brand Network
Vistagen to Announce Fiscal Year 2023 Financial Results and Provide Corporate Update Conference Call on June 28, 2023
From Vistagen
Via Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Regains Compliance with Nasdaq Listing Requirements
Via Investor Brand Network
Vistagen Regains Full Compliance with Nasdaq Listing Requirements
From Vistagen
Via Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Eyes Advancement of Itruvone into Phase 2B Development
Via Investor Brand Network
Vistagen Announces Results of Successful U.S. Phase 1 Study of Itruvone (PH10), Enabling U.S. Phase 2B Development for Treatment of Major Depressive Disorder
From Vistagen
Via Business Wire
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Announces Participation in Upcoming Maxim Group Healthcare Virtual Conference
Via Investor Brand Network
Vistagen to Participate in the Maxim Group Healthcare Virtual Conference Hosted by M-Vest
From Vistagen
Via Business Wire
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) PH80 Nasal Spray to Receive EPO Patent Approval
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Vistagen Announces European Patent Office Intention to Grant New PH80 Nasal Spray Patent for the Treatment of Migraine
From Vistagen
Via Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Positive Results from PH80 Exploratory Phase 2A Study
Via Investor Brand Network
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) to Participate in Upcoming Jefferies Global Healthcare Conference
Via Investor Brand Network
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 in Women Diagnosed with Menopausal Hot Flashes
From Vistagen
Via Business Wire
Vistagen to Present at Jefferies 2023 Global Healthcare Conference
From Vistagen
Via Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Implement Board-Approved Reverse Stock Split
Via Investor Brand Network
Vistagen Announces Stockholder-Approved Reverse Stock Split
From Vistagen
Via Business Wire
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Presents Phase 3 SAD Study Results at ASCP Annual Meeting
Via Investor Brand Network
Vistagen Presents Fasedienol (PH94B) Safety and Exploratory Efficacy Data from Phase 3 Open-Label Social Anxiety Disorder Study at American Society for Clinical Psychopharmacology Annual Meeting
From Vistagen
Via Business Wire
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) to Report Phase 3 Study Results at Upcoming ASCP Annual Meeting
Via Investor Brand Network
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.